Figures
Abstract
Tubulointerstitial fibrosis (TIF) is the final common pathway in the end-stage renal disease. Epithelial-to-mesenchymal transition (EMT) is considered a major contributor to the TIF by increasing the number of myofibroblasts. Curcumin, a polyphenolic compound derived from rhizomes of Curcuma, has been shown to possess potent anti-fibrotic properties but the mechanism remains elusive. We found that curcumin inhibited the EMT as assessed by reduced expression of α-SMA and PAI-1, and increased E-cadherin in TGF-β1 treated proximal tubular epithelial cell HK-2 cells. Both of the conventional TGF-β1/Smad pathway and non-Smad pathway were investigated. Curcumin reduced TGF-β receptor type I (TβR-I) and TGF-β receptor type II (TβR II), but had no effect on phosphorylation of Smad2 and Smad3. On the other hand, in non-Smad pathway curcumin reduced TGF-β1-induced ERK phosphorylation and PPARγ phosphorylation, and promoted nuclear translocation of PPARγ. Further, the effect of curcumin on α-SMA, PAI-1, E-cadherin, TβR I and TβR II were reversed by ERK inhibitor U0126 or PPARγ inhibitor BADGE, or PPARγ shRNA. Blocking PPARγ signaling pathway by inhibitor BADGE or shRNA had no effect on the phosphorylation of ERK whereas the suppression of ERK signaling pathway inhibited the phosphorylation of PPARγ. We conclude that curcumin counteracted TGF-β1-induced EMT in renal tubular epithelial cells via ERK-dependent and then PPARγ-dependent pathway.
Citation: Li R, Wang Y, Liu Y, Chen Q, Fu W, Wang H, et al. (2013) Curcumin Inhibits Transforming Growth Factor-β1-Induced EMT via PPARγ Pathway, Not Smad Pathway in Renal Tubular Epithelial Cells. PLoS ONE 8(3): e58848. https://doi.org/10.1371/journal.pone.0058848
Editor: Rajesh Mohanraj, UAE University, Faculty of Medicine & Health Sciences, United Arab Emirates
Received: December 9, 2012; Accepted: February 7, 2013; Published: March 27, 2013
Copyright: © 2013 Li et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research was supported by Natural Science Foundation of Shanghai (NO.11ZR1433200), Science Foundation of Shanghai Education Commission (NO.2010JW61), Science and Technology of Putuo District, Shanghai (NO.2008PTKW010) and the Innovation Team of the College of the Shanghai Municipal Education Commission, China. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Renal fibrosis, characterized by accumulation of fibroblasts and excessive matrix proteins along with loss of functioning nephrons, is a major pathological feature of progressive kidney disease. Tubulointerstitial fibrosis is considered the final common pathway of renal fibrosis. Recent studies have demonstrated that a critical step in the pathogenesis of tubulointerstitial fibrosis is Epithelial-mesenchymal transition (EMT) [1], a process whereby fully differentiated epithelial cells undergo transition to a mesenchymal phenotype. EMT causes a substantial increase in the number of myofibroblasts, one of main effector cells that contributes to the development of progressive renal fibrosis [2].
TGF-β is known as a major inducer of EMT. TGF-β1 induced EMT via Smad-dependent and Smad-independent pathways [3]. Through the Smad mediated pathway, TGF-β signals are transduced by transmembrane serine/threonine kinase type II and type I receptors (TβR II and TβR I) and intracellular mediators Smads [4]. In the non-Smad signaling pathway, TGF-β receptors interact with the MAPK pathway [5]. There are also reports that Peroxisome proliferator-activated receptor-γ (PPAR-γ) activation exerts antiproliferative and antifibrotic effects via the modulation of TGF-β1-mediated pathways [6].
PPAR-γ is a member of the nuclear receptor family of transcription factors. Ligands for PPAR-γ include a variety of natural and synthetic compounds. Synthetic ligands are often used as insulin sensitizing agents for treatment of type 2 diabetes [7]. Studies have demonstrated that PPARγ agonists exert protective effects in the models of renal diseases [8], [9]. PPARγ agonists rosiglitazone significantly attenuated glomerulosclerosis, tubulointerstitial expansion and collagen IV deposition in the apolipoprotein E knockout mouse [10]. Troglitazone, another PPARγ agonists, also attenuated renal interstitial fibrosis and inflammation in the unilateral ureteral obstruction's animal (UUO) [11], a classic renal fibrosis model.
Curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadience-3,5-dione] is a natural polyphenolic compound derived from the root of curcuma longa that has been widely used in India for medical, culinary and other purposes. A large body of evidence from in vitro and in vivo studies of both animals and human have indicated that curcumin exhibits a variety of biological effects such as anti-oxidant, anti-inflammatory, anti-tumor and wound healing properties [12]. In particular, some recent studies have shown that curcumin has anti-fibrotic effect in liver, lung and cystic fibrosis [13], [14], [15]. In UUO rat kidney fibrosis model curcumin has been reported to inhibit the renal interstitial inflammation and fibrosis by inhibiting of the NF-κB-dependent pathway [16]. In immortalized rat kidney interstitial fibroblasts (NRK/49F), curcumin attenuated TGF-β-induced fibrosis through down-regulation of TβR II [17].
Curcumin has been reported to activate PPAR-γ as well [18], but it is unclear the effect is depend on binding to the receptor of PPAR-γ [18] or is the result of indirect effects [19]. Thus, we hypothesized that curcumin may inhibit renal fibrosis as assessed by EMT through PPARγ pathways in the TGF-β signaling. On the other hand, researches on the anti-renal fibrosis effect of curcumin have been concentrated on the mediating role of Smad pathway and little is known about curcumin's effects through the non-Smad pathway such as MAPK, and whether there is any cross talk between MAPK and PPARγ is still elusive. Here, we reported the effect of curcumin on TGF-β1-induced EMT in renal tubular epithelial cells, and its underlying mechanisms related to non-Smad ERK1/2 and PPARγ pathways.
Materials and Methods
Cell culture and treatment
Human proximal tubular epithelial cells (HK-2 cells) were cultured in RPMI 1640 containing 2000 mg/L NaHCO3, supplemented with 10% FBS, 100 units/ml penicillin and 100 ug/ml streptomycin in an atmosphere of 5% carbon dioxide and 95% air at 37°C. Normal Rat Kidney(NRK-52E) proximal cells were cultured in DMEM containing 2000 mg/L NaHCO3, supplemented with 10% FBS, 100 units/ml penicillin and 100 ug/ml streptomycin in an atmosphere of 5% carbon dioxide and 95% air at 37°C.
At about 90% confluent, the cells were trypsinized by treatment with trypsin-EDTA and seeded in 6-well plates, grown to confluence, and rested in medium without FBS overnight.
Reagents
Curcumin [1,7-bis(4-hydroxy-3methoxyphenyl)-1,6-heptadiene-3,5-dione] was purchased from Sigma (St. Louis, MO, USA). Stock solutions of curcumin were prepared in dimethyl sulfoxide and used at a final concentration ≤0.1% (v/v). Recombinant Human transforming growth factor beta 1 (TGF-β1) were purchased from R&D Systems (USA). Antibodies to phospho-smad2, smad2, phospho-smad3, smad3, phospho-ERK1/2, ERK 1/2, PPARγ and TGF-β receptor II were purchased from Cell Signaling Technology (USA). Antibodies to p-PPARγ were purchased from Bioworld (USA). TGF-β receptor I was purchased from Santa Cruz Biotechnology (CA, USA). Antibodies to PAI-1, E-cadherin and α-SMA were purchased from Epitomics (USA). BCA Protein Assay Kit was purchased from Shanghai Biocolor BioScience & Technology Company (China).
Western blot analysis
At the time of harvest, cells were washed twice with PBS (135 mM, 2.7 mM KCL, 1.5 mM KH2PO4, 8 mM K2HPO4), homogenized in RIPA lysis buffer (150 mM NaCl, 1% Triton X-100, 0.1% SDS, 50 mM Tris-HCl pH 7.4, 1 mM EDTA, 1 mM PSFM). The supernatants were collected after centrifugation at 10,000×g at 4°C for 15 min. Protein concentration was determined using a BCA Protein Assay Kit. Equal amounts of protein were boiled at 95°C for 5 min after the addition of 5× Laemmli buffer. Protein samples were separated by 10% SDS gel electrophoresis (SDS-PAGE) and transferred to PVDF membranes. After blocking with 5% dry milk in Tris-buffered saline with 0.1% Tween (TBST) at room temperature for 2 h, the membranes were incubated with primary antibodies at 4°C overnight. After being washed in TBST three times, the membranes were incubated with horseradish peroxidase (HRP)-conjugated secondary antibody at room temperature for 1 h. The signals were visualized using the enhanced chemiluminescent (ECL) substrate.
Stable shRNA mediated repression of PPARγ in HK-2 cells
Human PPARγ expression in HK-2 cells was silenced by shRNA interference. The lentiviral mediated shRNA against PPARγ (NM_138712.3) system was purchased from Shanghai Sunbio Medical Biotechnology. An adopted non-silencing control shRNA sequence (TTCTCCGAACGTGTCACGT) that was not complementary to any human gene was used as a control shRNA. Lentiviruses were prepared in HEK293T cells followed by infecting HK-2 cells. Cells were selected using 0.5 μg/ml puromycin and subjected to western blot to test the expression level of PPARγ in the infected HK-2 cells.
Immunofluorescent staining and fluorescent microscopy
HK-2 cells grown on cover slips were washed with cold PBS three times and fixed in 5% paraformaldehyde for 25 minutes. The cells were then extensively washed three times each for 10 minutes with PBS and permeabilized with 0.1% TritonX-100 for 5 minutes. After blocking in 5% bovine serum albumin (BSA) in PBS buffer for 1 hour at room temperature, cells were incubated with the anti-PPARγ antibody at 4°C overnight with gentle rocking. Cells were next washed three times in PBS and stained with Cy-2-conjugated secondary antibody at room temperature for 2 hours. Stained cells were mounted with antifade mounting medium on slides and viewed with a fluorescence microscope.
Results
1. Curcumin inhibited the expression of α-SMA and PAI-1 and increased E-cadherin in TGF-β1 treated HK-2 cells
As shown in Fig. 1, the amount of α-SMA and PAI-1 proteins were very low while the epithelial cell marker, E-cadherin was prominent in normal HK-2 cells (Fig. 1 b). TGF-β1 induced a significant increase in α-SMA and PAI-1 and decrease in E-cadherin (Fig. 1 b & c). Curcumin down-regulated α-SMA and PAI-1 and up-regulated E-cadherin (Fig. 1 b & c).
HK-2 cells were incubated with curcumin at the indicated dose for 12 hours followed by treatment with TGF-β1 for 36 hours. (A) Effects of 10 μM of curcumin on morphology of HK-2 cells (B) Western blotting analyses for α-SMA, E-caherin and PAI-1 expression in HK-2 cells. (C) Graphical presentation of the relative expression of α-SMA, E-caherin and PAI-1. The values were represented as the density of α-SMA, E-caherin or PAI-1 vs β-actin (%). The mean ± SD (n = 3) of values were obtained from densitometric analysis of all individual experiments. *p<0.05 vs TGF-β1 alone.
2. Curcumin attenuated the TGF-β1-induced expression of TGF-β receptor type I (TβR I) and TGF-β receptor type II (TβR II) in HK-2 cells
Binding to the TGF-β receptor type II (TβR II) is the first step of TGF-β1 signaling, and the TβR II in turn phosphorylates TGF-β receptor type I (TβR I) [20]. To determine whether the anti EMT effect of curcumin is targeting TGF-β1-related signaling, we studied the effects of curcumim on TβR II and TβR I. As shown in Fig. 2, curcumin decreased both TβRI and TβR II expression in HK-2 cells.
HK-2 cells were incubated with curcumin at the indicated dose for 12 hours followed by treatment with TGF-β1 for 36 hours. (A) Western blotting analyses for TβR I and TβR II expression in HK-2 cells. (B) Graphical presentation of the relative expression of TβR I and TβR II. The values were represented as the density of TβR I or TβR II vs β-actin (%). The mean ± SD (n = 3) of values were obtained from densitometric analysis of all individual experiments. #P<0.05 vs. control alone, *P<0.05 vs TGF-β1 alone.
3. Effects of curcumin on TGF-β1-induced Smad2 and Smad3 phosphorylation in HK-2 cells
We then studied the effects of curcumin on Smad2 and Smad3, two important mediators of the TGF-β/Smads signaling, which has been known to play a major role in TGF-β1-induced EMT [21].
Smad2 and Smad3 were phoshorylated at 5 min and the phosphorylations reached the peak levels at 30 min (Fig. 3a). Pretreatment with curcumin for 12 hours and following by treatment with TGF-β1 for 30 minutes has no effect on phosphorylation of Smad2 and Smad3 (Fig. 3b). These data indicated that the inhibition of TGF-β1-induced EMT by curcumin is not through TGF-β/Smads signaling pathway.
(A) HK-2 cells were stimulates with TGF-β1 (2.5 ng/ml ) for the indicated times, and the phosphorylation of Smad2 and Smad3 were analyzed by western blotting. (B) Western blotting analyses for p-Smad2 and p-Smad3 expression in HK-2 cells. HK-2 cells were incubated with curcumin at the indicated doses for 12 hours followed by treatment with TGF-β1 for 30 minutes.
4. Curcumin reduced TGF-β1-induced ERK phosphorylation in HK-2 cells
Our studies showed that curcumin had little effect on TGF-β/Smads signaling. Since the activation of TβRI and TβR II can lead to the activation of other EMT associated signaling pathways, such as ERK [22], we examined the influence of curcumin on ERK signaling. ERK was phoshorylated at 5 min and reached the peak levels at 30 min post TGF-β1 treatment (Fig. 4a). Pretreatment with curcumin for 12 hours and following by treatment with TGF-β1 for 30 minutes decreased phosphorylation of ERK (Fig. 4b). These data indicated that curcumin may inhibit TGF-β1-induced EMT through ERK-related signaling pathway.
(A) HK-2 cells were stimulates with TGF-β1 (2.5 ng/ml ) for the indicated times, and the phosphorylation of ERK was analyzed by western blotting. (B) Western blotting analyses for p-ERK expression in HK-2 cells. HK-2 cells were incubated with curcumin at the indicated doses for 12 hours followed by treatment with TGF-β1 for 30 minutes. (C) Graphical presentation of the relative expression of pERK. The values were represented as the density of p-ERK vs total ERK (%). The mean ± SD (n = 3) of values were obtained from densitometric analysis of all individual experiments. #P<0.05 vs. control alone, *P<0.05 vs TGF-β1 alone.
5. Curcumin reduced TGF-β1-induced PPARγ phosphorylation and promoted nuclear translocation of PPARγ
Total PPARγ expression was reduced while its phosphorylation was increased after being treated with TGF-β1(Fig. 5). Pretreatment with curcumin for 12 hours increased PPARγ expression level and inhibited the phosphorylation of PPARγ. As expected, PPARγ agonist rosiglitazone increased PPARγ expression. We also found that rosiglitazone inhibited the phosphorylation of PPARγ. These results indicated that curcumin is a PPARγ agonist.
HK-2 cells were incubated with curcumin at the indicated dose for 12 hours or rosiglitazone for 1 hour followed by treatment with TGF-β1 for 36 hours. (A) Western blotting analyses for PPARγ and p-PPARγ expression in HK-2 cells. (B) Graphical presentation of the relative expression of PPARγ and p-PPARγ. The values were represented as the density of PPARγ and p-PPARγ vs β-actin (%). The mean ± SD (n = 3) of values were obtained from densitometric analysis of all individual experiments. #P<0.05 vs control alone, *P<0.05 vs TGF-β1 alone.
PPARγ is a nuclear transcription factor, which requires nuclear translocation. As shown in Fig. 6, TGF-β1 decreased the expression of PPARγ, and curcumin increased the expression of PPARγ and promoted nuclear translocation of PPARγ in HK-2 cells. Rosiglitazone also promoted nuclear translocation of PPARγ.
HK-2 cells were pretreated with curcumin (10 μM) for 12 hours (C) or rosiglitazone (10 μM) for 1 hour (D) following by incubated with TGF-β1 for 36 hours. Red for PPARγ.
6. ERK pharmacological inhibitor and PPARγ pharmacological inhibitor blocked the inhibitory effect of curcumin on TGF-β1-induced EMT of HK-2 cells
To elucidate whether the inhibition of ERK and PPARγ signaling are necessary for the effect of curcumin on TGF-β1-induced EMT of HK-2 cells, we pretreated HK-2 cells with U0126, a pharmacologcal inhibitor of ERK, or BADGE, a pharmacologcal inhibitor of PPARγ. In order to exclude the influence of curcumin or inhibitors on the protein expression, we have designed a control experiment with or without TGF-β1. As shown in Fig. 7a, in the absence of TGF-β1, curcumin, U0126, BADGE and curcumin combined with U0126, or BADGE did not have any effect on the protein levels of α-SMA, E-cadherin, PAI-1, TβRI and TβRII, and there was no significant difference compared with the control group. Similarly, in the presence of TGF-β1, U0126 or BADGE did not have any effect on establishment of model, and there was no significant difference compared with TGF-β1 treated group. Based on the above results, we studied the effects of curcumin with U0126 or BADGE on α-SMA, E-cadherin, PAI-1, TβR I and TβR II. The U0126 or BADGE treatment was shown to reverse the increases in α-SMA, PAI-1, TβR I and TβR II and the decreases in E-cadherin caused by curcumin (Fig. 7b).
(A) Effects of U0126, BADGE on the expression of α-SMA, PAI-1, E-cadherin, TβR I and TβR II with or without TGF-β1. HK-2 cells were pretreated with curcumin (10 μM) for 12 hours followed by treatment with U0126 (10 μM) or BADGE (10 μM) for 36 hours or HK-2 cells were pretreated with U0126 (10 μM) or BADGE (10 μM) for 1 hour before addition of TGF-β1 (2.5 ng/ml) for 36 hours. (B) Effects of curcmin on the expression of α-SMA, PAI-1, E-cadherin, TβR I and TβR II with TGF-β1 and U0126 or BADGE. HK-2 cells were pretreated with curcumin (10 μM) for 12 hours at indicated dose followed by treatment with U0126 (10 μM) or BADGE (10 μM) for 1 hour before addition of TGF-β1 (2.5 ng/ml) for 36 hours.
7. Effect of curcumin on TGF-β1-induced EMT in HK-2 cells is dependent on PPARγ
Furthermore, we knocked down the expression of PPARγ at cellular level using shRNA interference via lentiviral infection of HK-2 cells. Results from western blotting showed that the PPARγ protein in knocked-down cells was significantly lower compared to that in normal cells and scrambled shRNA infected cells (Fig. 8a). With the significantly decreased PPARγ expression by shRNA the effects of curcumin on α-SMA, PAI-1, E-cadherin, TβR I and TβR II were inhibited (Fig. 8b).
(A) Knockdown of PPARγ in HK-2 cells. HK-2 cells were infected with PPARγ-specific shRNA or scrambled shRNA for 3 hours and then changed the medium. The expression of PPARγ was examined by western blotting. (B) After infected with PPARγ-specific shRNA or scrambled shRNA for 3 hours, HK-2 cells were treated with curcumin (10 μM) for 12 hours at indicated dose followed by treatment with TGF-β1 (2.5 ng/ml) for 36 hours. Expression of α-SMA, PAI-1, E-cadherin, TβR II and TβR I were detected by western blotting.
8. ERK phoshorylates PPARγ in HK-2 cells
Blocking PPARγ signaling pathway by inhibitor BADGE or shRNA (Fig. 9a & 9b) had no effect on the phosphorylation of ERK whereas the suppression of ERK signaling pathway inhibited the phosphorylation of PPARγ (Fig. 9c). These data suggest that ERK signaling pathway is the upstream of PPARγ signaling pathway in the regulation of EMT in HK-2 cells.
(A) Effect of blocking PPARγ signaling by pharmacological inhibitor on phoshorylation of ERK. HK-2 cells were pretreated with BADGE (10 μM) 1 hour before addition of TGF-β1 (2.5 ng/ml) for 30 minutes and the expression of p-ERK were analyzed by western blotting. (B) Effect of knockdown of PPARγ at cellular level on phoshorylation of ERK. HK-2 cells infected with PPARγ-specific shRNA or scrambled shRNA were treated TGF-β1 (2.5 ng/ml) for 30 minutes and the expression of p-ERK were analyzed by western blotting. (C) Effect of blocking ERK signaling on phoshorylation of PPARγ. HK-2 cells were pretreated with U0126 (10 μM) for 1 hour before addition of TGF-β1 (2.5 ng/ml) for 36 hours and the expression of PPARγ were analyzed by western blotting.
9. Effect of curcumin on TGF-β1-induced EMT in NRK-52E cells
Curcumin is also able to block TGF-β1-induced EMT in NRF-52E cells, another renal tubular epithelial cell line (Fig. 10a). As shown in Fig. 10b & 10c, curcumin had no effect on p-Smad2 and p-Smad3, whereas reduced TGF-β1-induced PPARγ phosphorylation and increased the expression of total PPARγ, which is similar to the effects of curcumin on HK-2 cells.
NRK-52E cells were incubated with curcumin at the indicated dose for 12 hours followed by treatment with TGF-β1 for 36 hours(PAI-1, p-PPARγ and PPARγ) or 30 min(P-Smad2 and P-Smad3). (A) Western blotting analysis for PAI-1 expression. (B) Western blotting analysis for p-Smad2 and p-Smad3 expression. (C) Western blotting analysis for PPARγ and p-PPARγ expression.
Discussion
In this study, we investigated the effect of curcumin on TGF-β-induced EMT in HK-2 cells and the underlying mechanism. Increased expression of α-SMA and PAI-1 and decreased expression of E-cadherin are the hallmarks of renal tubular epithelial cells u ndergoing EMT [1], [23], [24]. Suppression of E-cadherin is considered the earliest changes in TGF-β1-induced EMT [25]. Α-SMA is an important marker of fibroblast, contributing to the morphology of the transfered cells and to their ability to migrate and invade. PAI-1, a potent inhibitor of uPA/tPA (urokinase/tissue-type plasminogen activators), plays a major role in extracellular matrix (ECM) accumulation and degradation [26], which is a principal feature in fibrosis. In this study, we observed that with pretreatment of curcumin, the increase of α-SMA and PAI-1 induced by TGF-β1 was attenuated, and the loss of E-cadherin was reversed, confirming the previous reports [17], [27]. These results indicated that curcumin inhibits the process of EMT in renal tubular cell lines.
The mechanisms underlying the effect of curcumin on EMT of HK-2 cells were further investigated. Since binding of TGF-β1 to TβR I and TβR II is the first step of TGF-β signaling [28], we first examined the effect of curcumin on the levels of TβR I and TβR II. Our studies showed that curcumin could inhibit the expression of both TβR I and TβR II, but Gaedeke et al found that curucmin selectively inhibited TβR II in renal fibroblasts cells. It suggested that the signaling might be diffent in tubular and fibroblasts cells.
TGF-β/Smads signaling is considered the most important pathway in EMT and most of the TGF-β-induced EMT appears to be dependent on this signaling. The phosphorylation of Smad2 and Smad3 are essential steps in the signaling cascade. Curcumin was previously demonstrated to suppress the phosphorylation of Smad2 but not that of Smad3 in HK-2 cells [27]. Li et al reported that curcumin inhibited the phosphorylations of both Smad2 and Smad3 in UUO rat model [29]. However, in our study, curcumin failed to affect the phosphorylations of both Smad2 and Smad3 and the expression of total Smad2 and Smad3 in HK-2 cells and NRK-52E cells. The different findings of the phosphorylations of Smad2 and Smad3 by curcumin treatment may be cell type specific, suggesting that the phosphorylation status and effect of Smad2 and Smad3 in EMT are complex and involve many factors.
Besides TGF-β/Smads pathway, TGF-β receptors activate some non-Smad signaling pathways as well, including ERK pathway et al. Studies have demonstrated that ERK is phoshorylated during TGF-β1-induced EMT [30], ERK activity is required for disassembly of adherens junctions and induction of cell motility, and blockade of ERK inhibited key morphological features of EMT in the mammary gland epithelial cells [31], hence the inhibition of phosphorylation of ERK is a potential target for suppressing renal fibrosis. In our study in HK-2 cells, ERK phosphorylation was detected at 5 min after treating with TGF-β1, whereas curcumin attenuated the TGF-β1-induced increase of p-ERK. We pretreated HK-2 cells with U0126, a pharmacological inhibitor of ERK, the inhibitory effect of curcumin on EMT was reduced, indicating that the inhibitory effect of curcumin on EMT is related to its inhibition on ERK signaling.
PPARγ is present and active in multiple renal cell type including the cultured glomerular mesangial cells, podocytes, proximal epithelial cells and epithelial cells of collecting ducts [32], [33]. Studies have shown that PPARγ agonists could ameliorate renal fibrotic lesions in diabetic nephropathy and nondiabetic chronic kidney diseases [34], [35], [36]. In this study, we demonstrated, for the first time, that curcumin induces the expression of PPARγ, inhibits the phosphorylation of PPARγ and promotes the nuclear translocation of PPARγ in renal tubular epithelial cells. Curcumin has been reported to activate PPARγ, but whether it is a ligand is still a debate [19]. The mechanisms by which curcumin induces PPARγ expression remain poorly understood. Two possibilities may be involved: firstly, curcumin binds to its own receptor and the complex stimulates the PPARγ signaling pathway resulting in the up-regulation of PPARγ [19]; secondly, curcumin is a ligand of PPARγ, and binds directly to PPARγ, leading to the activation of PPARγ [18]. Activation of PPARγ by curcumin is important for the inhibition of EMT by curcumin. Down-regulation of PPARγ by its pharmacology inhibitor BADGE or shRNA significantly weakened the inhibition of EMT by curcumin in HK-2 cells, indicating that PPARγ signaling is actively involved in EMT process and curcumin treatment. With both ERK pathway and PPARγ pathway implicated in the mechanism of the inhibition of EMT by curcumin, what is the cross talk between the two pathways in EMT in HK-2 cells? In the inflammatory animal model and cyst formation cell model, studies reported the activating effect of PPARγ by curcumin is attributed to its ability to reduce the intracellular protein p-ERK [37], [38], [39]. But the crosstalk between ERK and PPARγ is still controversial, and it is cell type-dependent. Two possible mechanisms are that either p-ERK phosphorylated and inactivated PPARγ or PPARγ activated ERK [40], [41], [42]. In HK-2 cell, it is very interesting to note in our study that the inhibition of PPARγ by shRNA or BADGE has no effect on the activation of ERK, whereas suppression of ERK using U0126 blocks the phosphorylation of PPARγ. These findings suggest that there is one way communication between ERK and PPARγ, in which ERK affects PPARγ but not in the reverse order in HK-2 cells.
In conclusion, our studies, for the first time, provided evidence for a protective role of curcumin in counteracting TGF-β1-induced EMT in renal tubular epithelial cells via ERK-dependent and then PPARγ-dependent pathway.
Author Contributions
Modified the draft: XMZ HC. Conceived and designed the experiments: XMZ WP. Performed the experiments: RL YMW. Analyzed the data: RL YJL. Contributed reagents/materials/analysis tools: WCF HW QJC. Wrote the paper: RL.
References
- 1. Zeisberg M, Kalluri R (2004) The role of epithelial-to-mesenchymal transition in renal fibrosis. Journal of Molecular Medicine 82: 175–181.
- 2. Yang J, Liu Y (2001) Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. The American Journal of Pathology 159: 1465–1475.
- 3. Derynck R, Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 425: 577–584.
- 4. Miyazono K, Ten Dijke P, Heldin CH (2000) TGF-β signaling by Smad proteins. Advances in immunology 75: 115–157.
- 5. Moustakas A, Heldin CH (2005) Non-Smad TGF-β signals. Journal of Cell Science 118: 3573–3584.
- 6. Kawai T, Masaki T, Doi S, Arakawa T, Yokoyama Y, et al. (2008) PPAR-γ agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-β. Laboratory Investigation 89: 47–58.
- 7. Berger J, Moller DE (2002) The mechanisms of action of PPARs. Annual review of medicine 53: 409–435.
- 8. Yang J, Zhang D, Li J, Zhang X, Fan F, et al. (2009) Role of PPARγ in renoprotection in Type 2 diabetes: molecular mechanisms and therapeutic potential. Clinical Science 116: 17.
- 9. Ma LJ, Marcantoni C, Linton MF, Fazio S, Fogo AB (2001) Peroxisome proliferator-activated receptor-γ agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney International 59: 1899–1910.
- 10. Akiyama TE, Sakai S, Lambert G, Nicol CJ, Matsusue K, et al. (2002) Conditional disruption of the peroxisome proliferator-activated receptor γ gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Molecular and Cellular Biology 22: 2607–2619.
- 11. Han JY, Kim YJ, Kim L, Choi SJ, Park IS, et al. (2010) PPARγ Agonist and Angiotensin II Receptor Antagonist Ameliorate Renal Tubulointerstitial Fibrosis. Journal of Korean medical science 25: 35.
- 12. Maheshwari RK, Singh AK, Gaddipati J, Srimal RC (2006) Multiple biological activities of curcumin: a short review. Life Sciences 78: 2081–2087.
- 13. Yao Q, Xu B, Wang J, Liu H, Zhang S, et al. (2012) Inhibition by curcumin of multiple sites of the transforming growth factor-beta1 signalling pathway ameliorates the progression of liver fibrosis induced by carbon tetrachloride in rats. BMC Complementary and Alternative Medicine 12: 156.
- 14. Punithavathi D, Venkatesan N, Babu M (2009) Curcumin inhibition of bleomycin-induced pulmonary fibrosis in rats. British Journal of Pharmacology 131: 169–172.
- 15. Lipecka J, Norez C, Bensalem N, Baudouin-Legros M, Planelles G, et al. (2006) Rescue of ΔF508-CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) by Curcumin: Involvement of the Keratin 18 Network. Journal of Pharmacology and Experimental Therapeutics 317: 500–505.
- 16. Kuwabara N, Tamada S, Iwai T, Teramoto K, Kaneda N, et al. (2006) Attenuation of renal fibrosis by curcumin in rat obstructive nephropathy. Urology 67: 440–446.
- 17. Gaedeke J, Noble NA, Border WA (2004) Curcumin blocks multiple sites of the TGF-b signaling cascade in renal cells. Kidney International 66: 112–120.
- 18. Chen A, Xu J (2005) Activation of PPARγ by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR. American Journal of Physiology-Gastrointestinal and Liver Physiology 288: G447–G456.
- 19. Narala VR, Smith MR, Adapala RK, Ranga R, Panati K, et al. (2009) Curcumin is not a ligand for peroxisome proliferator-activated receptor-gamma. Gene Ther Mol Biol 13: 20–25.
- 20. Wu MY, Hill CS (2009) TGF-β Superfamily Signaling in Embryonic Development and Homeostasis. Developmental Cell 16: 329–343.
- 21. Wang W, Koka V, Lan HY (2005) Transforming growth factor-β and Smad signalling in kidney diseases. Nephrology 10: 48–56.
- 22. Yan X, Liu Z, Chen Y (2009) Regulation of TGF-β signaling by Smad7. Acta Biochimica et Biophysica Sinica 41: 263–272.
- 23. Kalluri R, Neilson EG (2003) Epithelial-mesenchymal transition and its implications for fibrosis. Journal of Clinical Investigation 112: 1776–1784.
- 24. Zavadil J, Böttinger EP (2005) TGF-β and epithelial-to-mesenchymal transitions. Oncogene 24: 5764–5774.
- 25. Willis BC, Borok Z (2007) TGF-β-induced EMT: mechanisms and implications for fibrotic lung disease. American Journal of Physiology-Lung Cellular and Molecular Physiology 293: L525–L534.
- 26. Ghosh AK, Vaughan DE (2012) PAI-1 in tissue fibrosis. Journal of Cellular Physiology 227: 493–507.
- 27. Hu Y, Liang H, Du Y, Zhu Y, Wang X (2010) Curcumin Inhibits Transforming Growth Factor-β Activity via Inhibition of Smad Signaling in HK-2 Cells. American Journal of Nephrology 31: 332–341.
- 28. Rojas A, Padidam M, Cress D, Grady WM (2009) TGF-[beta] receptor levels regulate the specificity of signaling pathway activation and biological effects of TGF-[beta]. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1793: 1165–1173.
- 29. Li Y, Chen Z, Li Y (2011) Effects of curcumin on the epithelial mesenchymal transition and TGF-beta/Smads signaling pathway in unilateral ureteral obstruction rats. Zhongguo Zhong yi yan jiu yuan zhu ban 31: 1224.
- 30. Xie L, Law BK, Chytil AM, Brown KA, Aakre ME, et al. (2004) Activation of the Erk pathway is required for TGF-β1-induced EMT in vitro. Neoplasia (New York, NY) 6: 603.
- 31. Xie L, Law BK, Aakre ME, Edgerton M, Shyr Y, et al. (2003) Transforming growth factor beta-regulated gene expression in a mouse mammary gland epithelial cell line. Breast Cancer Res 5: R187–R198.
- 32. Abbott BD (2009) Review of the expression of peroxisome proliferator-activated receptors alpha (PPARα), beta (PPARβ), and gamma (PPARγ) in rodent and human development. Reproductive Toxicology 27: 246–257.
- 33. Kiss-Tóth É, Rőszer T (2008) PPARγ in Kidney Physiology and Pathophysiology. PPAR Research 2008: 183108.
- 34. Panchapakesan U, Sumual S, Pollock CA, Chen X (2005) PPARγ agonists exert antifibrotic effects in renal tubular cells exposed to high glucose. American Journal of Physiology-Renal Physiology 289: F1153–F1158.
- 35. Ko GJ, Kang YS, Han SY, Lee MH, Song HK, et al. (2008) Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Nephrology Dialysis Transplantation 23: 2750–2760.
- 36. Chung B, Lim S, Ahn K, Sugawara A, Ito S, et al. (2005) Protective effect of peroxisome proliferator activated receptor gamma agonists on diabetic and non-diabetic renal diseases. Nephrology 10: S40–S43.
- 37. Chen A, Zheng S (2009) Curcumin inhibits connective tissue growth factor gene expression in activated hepatic stellate cells in vitro by blocking NF-κB and ERK signalling. British Journal of Pharmacology 153: 557–567.
- 38. Ghosh SS, Massey HD, Krieg R, Fazelbhoy ZA, Ghosh S, et al. (2009) Curcumin ameliorates renal ailure in 5/6 nephrectomized rats: role of inflammation. American Journal of Physiology-Renal Physiology 296: F1146–F1157.
- 39. Gao J, Zhou H, Lei T, Zhou L, Li W, et al. (2011) Curcumin inhibits renal cyst formation and enlargement in vitro by regulating intracellular signaling pathways. European journal of pharmacology 654: 92–99.
- 40. Diradourian C, Girard J, Pégorier JP (2005) Phosphorylation of PPARs: from molecular characterization to physiological relevance. Biochimie 87: 33–38.
- 41. Rochette-Egly C (2003) Nuclear receptors: integration of multiple signalling pathways through phosphorylation. Cellular Signalling 15: 355–366.
- 42. Burgermeister E, Seger R (2008) PPARγ and MEK Interactions in Cancer. PPAR Research 2008: 1–16.